Allopurinol-Induced Stevens-Johnson Syndrome (SJS)
Allopurinol is a commonly used medication that lowers uric acid production which is essential for gout treatment and prevention. Although many patients tolerate allopurinol therapy without severe complications; Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are life-threatening...
Gespeichert in:
Veröffentlicht in: | Clinical pharmacology : advances and applications 2023, Vol.15, p.99-105 |
---|---|
Hauptverfasser: | , |
Format: | Report |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 105 |
---|---|
container_issue | |
container_start_page | 99 |
container_title | Clinical pharmacology : advances and applications |
container_volume | 15 |
creator | Anis, Takla R Meher, John |
description | Allopurinol is a commonly used medication that lowers uric acid production which is essential for gout treatment and prevention. Although many patients tolerate allopurinol therapy without severe complications; Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are life-threatening delayed hypersensitivity reactions that have been reported especially among Asian and African American patients. We describe a case of allopurinol-induced SJS in a 95-year-old Asian female. The patient started allopurinol 13 days prior to presenting to the emergency room (ER). On day 10 of therapy, the patient developed a diffuse erythematous desquamating rash which prompted her to visit the ER after 3 days from the rash onset. This case report describes a rare fatal hypersensitivity reaction that requires rapid identification and treatment in a multi-disciplinary setting. |
doi_str_mv | 10.2147/CPAA.S427714 |
format | Report |
fullrecord | <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_miscellaneous_2874839685</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2874839685</sourcerecordid><originalsourceid>FETCH-proquest_miscellaneous_28748396853</originalsourceid><addsrcrecordid>eNqVijEOgjAAABujiUTZfAAjDsW2FFpGQjTKZFJ3QqBGTGmRUhN_r4ODq7fcDQfABqOIYMp2xTnPI0EJY5jOgIcxyyCmMZ__9BL41t7RhwShjKceILlSZnBjp42CJ926RraBmORTagtLc9PW6EC8dDuaXgahKMV2DRbXWlnpf70C4WF_KY5wGM3DSTtVfWcbqVStpXG2IpxRHmcpT-I_1jf5mj33</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>report</recordtype><pqid>2874839685</pqid></control><display><type>report</type><title>Allopurinol-Induced Stevens-Johnson Syndrome (SJS)</title><source>Taylor & Francis Open Access</source><source>DOVE Medical Press Journals</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>PubMed Central</source><creator>Anis, Takla R ; Meher, John</creator><creatorcontrib>Anis, Takla R ; Meher, John</creatorcontrib><description>Allopurinol is a commonly used medication that lowers uric acid production which is essential for gout treatment and prevention. Although many patients tolerate allopurinol therapy without severe complications; Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are life-threatening delayed hypersensitivity reactions that have been reported especially among Asian and African American patients. We describe a case of allopurinol-induced SJS in a 95-year-old Asian female. The patient started allopurinol 13 days prior to presenting to the emergency room (ER). On day 10 of therapy, the patient developed a diffuse erythematous desquamating rash which prompted her to visit the ER after 3 days from the rash onset. This case report describes a rare fatal hypersensitivity reaction that requires rapid identification and treatment in a multi-disciplinary setting.</description><identifier>ISSN: 1179-1438</identifier><identifier>EISSN: 1179-1438</identifier><identifier>DOI: 10.2147/CPAA.S427714</identifier><language>eng</language><ispartof>Clinical pharmacology : advances and applications, 2023, Vol.15, p.99-105</ispartof><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>778,782,862,4478,27912</link.rule.ids></links><search><creatorcontrib>Anis, Takla R</creatorcontrib><creatorcontrib>Meher, John</creatorcontrib><title>Allopurinol-Induced Stevens-Johnson Syndrome (SJS)</title><title>Clinical pharmacology : advances and applications</title><description>Allopurinol is a commonly used medication that lowers uric acid production which is essential for gout treatment and prevention. Although many patients tolerate allopurinol therapy without severe complications; Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are life-threatening delayed hypersensitivity reactions that have been reported especially among Asian and African American patients. We describe a case of allopurinol-induced SJS in a 95-year-old Asian female. The patient started allopurinol 13 days prior to presenting to the emergency room (ER). On day 10 of therapy, the patient developed a diffuse erythematous desquamating rash which prompted her to visit the ER after 3 days from the rash onset. This case report describes a rare fatal hypersensitivity reaction that requires rapid identification and treatment in a multi-disciplinary setting.</description><issn>1179-1438</issn><issn>1179-1438</issn><fulltext>true</fulltext><rsrctype>report</rsrctype><creationdate>2023</creationdate><recordtype>report</recordtype><recordid>eNqVijEOgjAAABujiUTZfAAjDsW2FFpGQjTKZFJ3QqBGTGmRUhN_r4ODq7fcDQfABqOIYMp2xTnPI0EJY5jOgIcxyyCmMZ__9BL41t7RhwShjKceILlSZnBjp42CJ926RraBmORTagtLc9PW6EC8dDuaXgahKMV2DRbXWlnpf70C4WF_KY5wGM3DSTtVfWcbqVStpXG2IpxRHmcpT-I_1jf5mj33</recordid><startdate>20230101</startdate><enddate>20230101</enddate><creator>Anis, Takla R</creator><creator>Meher, John</creator><scope>7X8</scope></search><sort><creationdate>20230101</creationdate><title>Allopurinol-Induced Stevens-Johnson Syndrome (SJS)</title><author>Anis, Takla R ; Meher, John</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_miscellaneous_28748396853</frbrgroupid><rsrctype>reports</rsrctype><prefilter>reports</prefilter><language>eng</language><creationdate>2023</creationdate><toplevel>online_resources</toplevel><creatorcontrib>Anis, Takla R</creatorcontrib><creatorcontrib>Meher, John</creatorcontrib><collection>MEDLINE - Academic</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Anis, Takla R</au><au>Meher, John</au><format>book</format><genre>unknown</genre><ristype>RPRT</ristype><atitle>Allopurinol-Induced Stevens-Johnson Syndrome (SJS)</atitle><jtitle>Clinical pharmacology : advances and applications</jtitle><date>2023-01-01</date><risdate>2023</risdate><volume>15</volume><spage>99</spage><epage>105</epage><pages>99-105</pages><issn>1179-1438</issn><eissn>1179-1438</eissn><abstract>Allopurinol is a commonly used medication that lowers uric acid production which is essential for gout treatment and prevention. Although many patients tolerate allopurinol therapy without severe complications; Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are life-threatening delayed hypersensitivity reactions that have been reported especially among Asian and African American patients. We describe a case of allopurinol-induced SJS in a 95-year-old Asian female. The patient started allopurinol 13 days prior to presenting to the emergency room (ER). On day 10 of therapy, the patient developed a diffuse erythematous desquamating rash which prompted her to visit the ER after 3 days from the rash onset. This case report describes a rare fatal hypersensitivity reaction that requires rapid identification and treatment in a multi-disciplinary setting.</abstract><doi>10.2147/CPAA.S427714</doi></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1179-1438 |
ispartof | Clinical pharmacology : advances and applications, 2023, Vol.15, p.99-105 |
issn | 1179-1438 1179-1438 |
language | eng |
recordid | cdi_proquest_miscellaneous_2874839685 |
source | Taylor & Francis Open Access; DOVE Medical Press Journals; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; PubMed Central |
title | Allopurinol-Induced Stevens-Johnson Syndrome (SJS) |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T03%3A04%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:book&rft.genre=unknown&rft.atitle=Allopurinol-Induced%20Stevens-Johnson%20Syndrome%20(SJS)&rft.jtitle=Clinical%20pharmacology%20:%20advances%20and%20applications&rft.au=Anis,%20Takla%20R&rft.date=2023-01-01&rft.volume=15&rft.spage=99&rft.epage=105&rft.pages=99-105&rft.issn=1179-1438&rft.eissn=1179-1438&rft_id=info:doi/10.2147/CPAA.S427714&rft_dat=%3Cproquest%3E2874839685%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2874839685&rft_id=info:pmid/&rfr_iscdi=true |